Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 13Kidney Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 5von Hippel-Lindau Disease 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Glioblastoma 1

Interventions

belzutifan 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × von Hippel-Lindau Disease × belzutifan × Clear all
NCT03401788 2026-04-13

MK-6482-004

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Active not recruiting
50 enrolled 1 FDA

von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡